Literature DB >> 8637513

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.

C Conry-Cantilena1, M VanRaden, J Gibble, J Melpolder, A O Shakil, L Viladomiu, L Cheung, A DiBisceglie, J Hoofnagle, J W Shih.   

Abstract

BACKGROUND: For many people infected with the hepatitis C virus (HCV), the route of exposure, risk of transmission, and severity of associated liver disease are unknown. We studied these variables in people who donated blood voluntarily.
METHODS: Blood donors who tested positive for HCV antibodies on enzyme immunoassay were classified according to whether the results of a confirmatory second-generation recombinant immunoblot assay (RIBA) for HCV were positive, negative, or indeterminate. The evaluations also included an assessment of risk factors, a physical examination, serial determinations of alanine aminotransferase levels and HCV serologic assays, a polymerase-chain-reaction assay for HCV RNA, testing of sexual contacts and family members, and liver biopsies in some participants who were HCV-positive by RIBA.
RESULTS: A total of 481 donors were studied, among whom 248 were positive for HCV by RIBA, 102 had indeterminate results, and 131 were HCV-negative. In a logistic-regression analysis, significant risk factors for HCV infection among the HCV-positive participants were a history of blood transfusion in 66 (27 percent; P < 0.001 for the comparison with RIBA-negative donors), intranasal cocaine use in 169 (68 percent, P < 0.001), intravenous drug use in 103 (42 percent, P = 0.001), sexual promiscuity in 132 (53 percent, P = 0.002), and ear piercing among men (P < 0.05). Nine of 85 sexual partners of HCV-positive donors were anti-HCV-positive; 8 had used intravenous drugs or received transfusions. HCV RNA was found in 213 HCV-positive donors (86 percent), 3 who had indeterminate results by RIBA (2 of these 3 tested positive with a more specific, third-generation RIBA), and none who were HCV-negative. Of the HCV-positive donors, 69 percent had biochemical evidence of chronic liver disease; among 77 donors positive for HCV by RIBA who underwent liver biopsy, 5 had severe chronic hepatitis or cirrhosis, 66 had mild-to-moderate chronic hepatitis, and 6 had no evidence of hepatitis.
CONCLUSIONS: Among volunteer blood donors, prior blood transfusion, intranasal cocaine use, intravenous drug use, sexual promiscuity, and ear piercing in men are risk factors for HCV infection. The high frequency of intravenous drug use was unexpected, because these donors had denied such use when questioned directly at the time of their blood donations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637513     DOI: 10.1056/NEJM199606273342602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

1.  A study on the role of the family and other risk factors in HCV transmission.

Authors:  S Brusaferro; F Barbone; P Andrian; G Brianti; L Ciccone; A Furlan; D Gnesutta; S Stel; E Zamparo; P Toniutto; P Ferroni; V Gasparini
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

Review 2.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

3.  Hepatitis C virus infection in cocaine users--a silent epidemic.

Authors:  H H Harsch; J Pankiewicz; A S Bloom; C Rainey; J K Cho; L Sperry; E A Stein
Journal:  Community Ment Health J       Date:  2000-06

4.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

5.  Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

6.  Investigation of residual hepatitis C virus in presumed recovered subjects.

Authors:  Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

7.  The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling.

Authors:  Addisalem T Makuria; Sukanya Raghuraman; Peter D Burbelo; Cathy C Cantilena; Robert D Allison; Joan Gibble; Barbara Rehermann; Harvey J Alter
Journal:  Transfusion       Date:  2012-02-05       Impact factor: 3.157

Review 8.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

9.  Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA.

Authors:  J T Stapleton; D Klinzman; W N Schmidt; M A Pfaller; P Wu; D R LaBrecque; J q Han; M J Phillips; R Woolson; B Alden
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Risk factors for hepatitis C virus infection among blood donors in Georgia.

Authors:  Nickolas Zaller; Kenrad E Nelson; Malvina Aladashvili; Nino Badridze; Carlos del Rio; Tengiz Tsertsvadze
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.